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Background: Recent findings of rapid lung function decline in younger patients with moderate
COPD severity suggest the need for effective early treatment.
Aim: To evaluate the effectiveness of indacaterol as maintenance therapy in COPD patients
not receiving other maintenance treatments.
Methods: Pooled data from three randomised, placebo-controlled studies provided a popula-
tion of patients with moderate-to-severe COPD not receiving maintenance treatment at base-
line and who received once-daily, double-blind treatment with indacaterol 150 mg, indacaterol
300 mg or placebo. Data from an open-label tiotropium treatment arm in one study were avail-
able for comparison. Efficacy evaluations included trough FEV1, dyspnoea (transition dyspnoea
index, TDI) and health status (St George’s Respiratory Questionnaire, SGRQ) at 6 months and
risk of COPD exacerbations.
Results: The maintenance-naı¨ve population comprised 232 (indacaterol 150 mg), 220 (indaca-
terol 300 mg) and 325 (placebo) patients, plus 156 (tiotropium) (30% of overall study popula-
tion). Patients treated with indacaterol 150 and 300 mg had statistically significant
improvements relative to placebo (p < 0.05) in trough FEV1 (170 and 180 mL), TDI total score
(1.27 and 1.04 points), rescue use and SGRQ total score (6.1 and 2.5 units) at 6 months.
Patients receiving tiotropium had statistically significant improvements versus placebo
(p < 0.05) in trough FEV1 (130 mL) and TDI total score (0.69 points). Exacerbations were rare
and not significantly reduced by any treatment. Treatments were well tolerated.
Conclusions: Indacaterol, given to patients with moderate-to-severe COPD not receiving other
maintenance treatments, provided effective bronchodilation with significant, clinically rele-
vant improvements in dyspnoea and health status compared with placebo.
ª 2012 Elsevier Ltd. All rights reserved.6 346807; fax: þ32 16 346803.
zleuven.be (M. Decramer).
2 Elsevier Ltd. All rights reserved.
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approved for use in COPD, and the twice-daily bronchodi-The strategy for maintenance pharmacological treatment
of chronic obstructive pulmonary disease (COPD) centres
largely on the use of long-acting bronchodilators, with fixed
combinations of long-acting bronchodilator and inhaled
corticosteroid (ICS) for patients at high risk of exacerba-
tions.1 Large-scale studies have suggested that both these
treatment modalities may reduce the rate of decline in lung
function and are associated with trends for reduced mor-
tality,2e5 although the evidence is not regarded as
conclusive.1
The effect of treatment on lung function decline may be
more marked in patients who are younger and in those with
less severe disease.4,6e8 Recent studies have shown that
lung function deteriorates more rapidly during the less
severe, early stages of COPD,7,9,10 strengthening the
rationale for early pharmacological treatment. Long-acting
bronchodilators, either of the b2-agonist (LABA) or anti-
muscarinic (LAMA) type, are the recommended initial
maintenance strategy for COPD patients who are symp-
tomatic but at low risk of exacerbations.1 However, there is
a relative lack of outcomes data with which to evaluate the
effectiveness and safety of such treatments as initial
maintenance therapies for patients with COPD.
Clinical studies with the once-daily LABA indacaterol
have evaluated its effectiveness in patients with
moderate-to-severe COPD, including some patients who
had not previously received maintenance COPD treatment.
To provide further insight into the use of long-acting
bronchodilators as initial maintenance therapy, we con-
ducted a retrospective analysis of pooled data from three
placebo-controlled studies11e13 in a subgroup of patients
defined by the absence of maintenance treatment for
COPD at the baselines of the studies. Efficacy and tolera-
bility of indacaterol are described. Efficacy outcomes re-
ported here include the bronchodilator effect over 6
months of treatment, as well as the important COPD
outcomes of health status, dyspnoea and exacerbations.
Results obtained from an open-label treatment arm with
the LAMA tiotropium in one of the source studies are
included for comparison. Results for the remainder of the
patients from these studies, the larger subgroup who were
receiving maintenance COPD treatments at baseline, are
also included.
Methods
Study design and patients
Data were pooled from three randomised, double-blind,
placebo-controlled studies (Clinicaltrials.gov identifiers
NCT00393458, NCT00463567 and NCT00567996). One study
compared indacaterol 150 mg once daily with placebo,
taken for 6 months11; one study compared indacaterol
300 mg once daily with placebo taken for 1 year,12 and the
third study compared once-daily indacaterol 150 mg, inda-
caterol 300 mg and placebo taken for 6 months.13 The third
study also included an open-label treatment arm with once-
daily tiotropium 18 mg.13 Data from the other treatment
groups included in the studies are not reported here(a 600 mg once-daily dose of indacaterol, because it is not
lators formoterol and salmeterol, because they are not
commonly used as monotherapy in COPD).
The three studies enrolled men and women aged 40
years with moderate-to-severe COPD (defined by Global
initiative for chronic Obstructive Lung Disease [GOLD] 2005
spirometric criteria), with a smoking history 20 pack-years
and post-bronchodilator FEV1<80% and30% predicted and
forced expiratory volume in 1 s (FEV1)/forced vital capacity
<70%. Patients with a history of asthma, or a recent COPD
exacerbation or respiratory tract infection, were not
included. Patients were allowed to use salbutamol as
required as rescue medication during the study treatment
periods. Specifically with respect to the subgroup of
patients who were receiving maintenance treatment at
baseline, patients receiving ICS alone or in combination with
a long-acting bronchodilator continued ICS alone at the
same or equivalent dose and regimen during the studies;
other maintenance treatments were discontinued with
appropriate washouts before study treatment commenced.
Full details of the designs and enrolment criteria of the
individual studies have been published previously.11e13Assessments and variables
Assessments were conducted for the subgroup of mainte-
nance-naı¨ve patients within the pooled population from the
three studies (30% of total patients). Maintenance-naı¨ve
patients were defined as those who did not use medications
classed as a corticosteroid, xanthine, anticholinergic,
b2-agonist plus steroid, bronchodilator combination,
b2-agonist plus anticholinergic, LABA, LAMA or short-acting
muscarinic antagonist at enrolment or during the study. Use
of a short-acting b2-agonist was permitted as rescue
medication for symptom relief.
The bronchodilator effect of treatment was measured as
‘trough’ (24 h post-dose) FEV1 after 6 months of treatment
(Week 26). A difference versus placebo of 120 mL was
considered clinically important based on the 100e140 mL
range reported as the minimal clinically important differ-
ence (MCID) by the American Thoracic Society/European
Respiratory Society.14 Dyspnoea was measured as transition
dyspnoea index (TDI) total score at Week 26 and the
percentage of patients responding with at least the MCID
improvement of þ1 point in TDI total score.15e17 The use of
short-acting b2-agonist (salbutamol) as rescue medication
was measured as the percentage of days with no rescue use
and the daily use over 26 weeks. Health status was assessed
as St George’s Respiratory Questionnaire (SGRQ) total score
at Week 26 and the percentage of patients responding with
at least the MCID improvement of 4 units in SGRQ total
score.18 A COPD exacerbation was defined as the onset or
worsening of more than one respiratory symptom (i.e.
dyspnoea, cough, sputum purulence or volume, or wheeze)
for >3 consecutive days, plus a documented change in
COPD-related treatment due to worsening symptoms (e.g.
corticosteroids, antibiotics, oxygen) and/or a documented
COPD-related hospitalisation or emergency room visit.
Adverse events and serious adverse events were recorded
and are summarised here.
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Trough FEV1 after 26 weeks of treatment was analysed
using a mixed-effect model analysis of covariance with
treatment, smoking status, country, and study as fixed
effects and baseline FEV1 and FEV1 reversibility as cova-
riates. Centre nested within country was also included as
a random effect. Missing values were imputed by carrying
forward the last observation, but not by more than 14
weeks. The same model (with appropriate covariates) was
used to analyse mean TDI and SGRQ scores, rescue use and
percentage of days with no rescue use. Data are presented
as least squares means with standard errors or associated
95% confidence intervals (CI) for differences between
treatments. The proportions of patients who achieved the
MCID improvement in TDI or SGRQ (changes of þ1 and 4
points respectively) were analysed using logistic regression.
The model included the same covariates as for trough FEV1
but with the inclusion of the appropriate baseline value.
The estimated adjusted odds ratios were displayed along
with the associated 95% CI. Time to first COPD exacerbation
was analysed by Cox regression model, which was stratified
by country and study and included the terms for treatment,
smoking status, baseline COPD exacerbation history (yes,
no), and FEV1 salbutamol reversibility components.
Patients without a COPD exacerbation were censored at the
date of the last medication intake. Results are expressed as
hazard ratios with associated 95% CI. No powering or
sample size calculations were performed for this post-hoc
analysis, and no adjustment was made for multiplicity.
Results
Patient disposition and baseline characteristics
The maintenance-naı¨ve population (30% of the total study
population) comprised 232 patients receiving indacaterol
150 mg, 220 receiving indacaterol 300 mg and 325 receiving
placebo; 156 received open-label tiotropium 18 mg. Patient
disposition is shown in Fig. 1, including reasons for early
discontinuation. Of the four deaths listed here, one (inda-
caterol 150 mg) was due to sudden cardiac arrest, one
(indacaterol 300 mg) was due to a possible myocardial
infarction, and the two deaths in the placebo group were
due to possible myocardial infarction and unknown causes.
Baseline demographic and clinical characteristics were
generally well balanced between treatment groups
(Table 1). Between 62% and 70% of patients had airflow
obstruction of GOLD stage I or II, 30e39% GOLD III or IV. The
three original studies enrolled a small proportion of
patients with severity GOLD I (3.6%) or GOLD IV (1.2%), so
the vast majority of patients in these categories were GOLD
II or GOLD III. The baseline SGRQ scores of 42e44 reflect
a substantial impairment in health status compared with
values of approximately 7e10 units obtained in samples
from the general population.19,20
Data for the subgroup of patients who were receiving
maintenance treatment at baseline (70% of total patients)
are in the online supplement. Patients in this subgroup
(online Table S1) were approximately 2 years older with
a similarly longer duration of COPD and an overall profile ofmore severe disease compared with the maintenance-naı¨ve
group. Approximately 60% were receiving ICS.Efficacy
Indacaterol had clinically relevant (120 mL) and statisti-
cally significant (p < 0.001) effects on trough FEV1 versus
placebo at Week 26 (Fig. 2). Open-label tiotropium had
similar effects on trough FEV1 and the difference of
30e40 mL between indacaterol and tiotropium was not
statistically significant. Similar results were obtained in the
maintenance subgroup (online Table S2).
Compared with placebo, there were statistically signifi-
cant differences in TDI total scores at Week 26 for both
indacaterol doses (p < 0.001), with differences versus
placebo above the MCID (Table 2). Open-label tiotropium
had a significant effect versus placebo (p < 0.05) for TDI
total score at Week 26 although the difference was below
the MCID (Table 2). During the 26 weeks, patients receiving
indacaterol 150 and 300 mg had a higher mean percentage
of days without rescue use relative to placebo, while the
difference versus placebo in patients receiving open-label
tiotropium (equating to 1 day) was not significant (Table
2). In the maintenance subgroup, TDI scores and rescue
use assessments were significantly improved with active
treatments compared with placebo (online Table S2).
Patients receiving indacaterol (either dose) had a 2.5-fold
higher likelihood of having a clinically significant improve-
ment in TDI score than those receiving placebo (Fig. 3). In
patients receiving open-label tiotropium, the likelihood of
a clinically significant improvement in TDI score was 1.8-
fold higher than in the placebo group (Fig. 3).
Mean treatment differences in SGRQ total scores versus
placebo were statistically significant in the indacaterol 150
and 300 mg groups (6.1 and 2.5 units, respectively), but
not in the open-label tiotropium group (1.6). The differ-
ence between indacaterol 150 mg and placebo was above
the MCID. Raw mean changes from baseline in SGRQ total
scores were greater than the MCID in all treatment groups,
including placebo (from 10.8 units with indacaterol 150 mg
to 5.2 with placebo) (Table 2). The likelihood of having
a clinically significant improvement in SGRQ total score was
significantly greater with indacaterol (both doses) than
placebo, but not with open-label tiotropium versus placebo
(Fig. 4).
In the subgroup of patients on maintenance treatment at
baseline, odds ratios for achieving the MCID in TDI and SGRQ
total scores were significantly improved relative to placebo
with indacaterol 150 mg and 300 mg, but not with open-label
tiotropium (online Table S3).Exacerbations
Exacerbations were rare in all the treatment groups in the
maintenance-naı¨ve subgroup patients, with annualised
rates of 0.09 and 0.12 with indacaterol 150 mg and 300 mg,
0.06 with tiotropium and 0.16 with placebo. Hazard ratios
of time-to-first exacerbation showed no significant effect of
any active treatment on risk of exacerbation compared
with placebo: indacaterol 150 mg, 0.73 (95% CI 0.03e1.78);
Randomized
n=933
Indacaterol 150 µg
n=232 (100%)
Completed
26 weeks
n=180 (77.6%)
Discontinued:
• Adverse event 9
• Abnormal lab value 1
• Abnormal test procedure 2
• Withdrawn consent 18
• Lost to follow-up 11
• Administrative problem 2
• Death 1
• Protocol deviation 8
• Unsatisfactory therapeutic 
effect 0
Indacaterol 300 µg
n=220 (100%)
Completed
26 weeks
n=182 (82.7%)
Discontinued:
• Adverse event: 8
• Abnormal lab value 1
• Abnormal test procedure 0
• Withdrawn consent 13
• Lost to follow-up 4
• Administrative problem 1
• Death 1
• Protocol deviation 7
• Unsatisfactory therapeutic 
effect 3
Tiotropium (open label)
n=156 (100%)
Completed
26 weeks
n=122 (78.2%)
Discontinued:
• Adverse event: 8
• Abnormal lab value 2 
• Abnormal test procedure 2
• Withdrawn consent 9
• Lost to follow-up 8
• Administrative problem 0
• Death 0
• Protocol deviation 5
• Unsatisfactory therapeutic 
effect 0
Placebo
n=325 (100%)
Completed
26 weeks
n=239 (73.5%)
Discontinued:
• Adverse event: 19
• Abnormal lab value 0 
• Abnormal test procedure 2
• Withdrawn consent 28
• Lost to follow-up 11
• Administrative problem 4
• Death 2
• Protocol deviation 10
• Unsatisfactory therapeutic 
effect 10
Figure 1 Patient disposition.
Table 1 Demographic and clinical characteristics at baseline.
Indacaterol Tiotropium 18 mg
(open label)
Placebo
150 mg 300 mg
Patients, n 232 220 156 325
Age, years 62 (9.0) 62 (9.4) 62 (9.1) 62 (9.2)
Male, % 73 74 69 74
COPD duration, years 5.4 (5.92) 5.0 (5.21) 5.4 (5.77) 5.5 (6.08)
GOLD stage, n (%)
Stage I or II 162 (69.8) 156 (70.9) 96 (61.5) 216 (66.5)
Stage III or IV 70 (30.2) 64 (29.1) 60 (38.5) 109 (33.5)
FEV1, % predicted
b 59 (15.2) 59 (14.4) 57 (16.4) 58 (14.7)
Mean (SD) FEV1, L
Pre-bronchodilatora 1.48 (0.493) 1.50 (0.507) 1.44 (0.521) 1.45 (0.505)
Post-bronchodilatorb 1.63 (0.508) 1.67 (0.526) 1.58 (0.550) 1.61 (0.515)
FEV1 reversibility, % 12.0 (12.53) 13.3 (12.97) 12.0 (17.1) 13.0 (14.58)
FEV1/FVC post-bronchodilator,
b % 55 (10.0) 53 (10.2) 55 (9.5) 55 (10.3)
Smoking history, n (%)
Ex-smoker/current smoker, % 47/53 48/52 46/54 50/50
Baseline dyspnoea index score 7.1 (2.24) 6.8 (2.21) 6.9 (2.18) 6.9 (2.56)
Baseline SGRQ score 42 (19.1) 44 (19.1) 44 (18.4) 43 (18.8)
Data are mean standard deviation unless otherwise stated.
FEV1 Z forced expiratory volume in 1 s; FVC Z forced vital capacity; SD Z standard deviation; SGRQ Z St George’s Respiratory
Questionnaire.
a Before administration of salbutamol 400 mg.
b 30 min after administration of salbutamol 400 mg.
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Figure 2 Effect of active treatments (differences compared
with placebo) on trough FEV1 at Week 26. Data are least
squares means with 95% CI. ap < 0.001 versus placebo. The
broken line indicates minimum clinically important difference.
1710 M. Decramer et al.indacaterol 300 mg, 0.82 (95% CI); open-label tiotropium,
0.71 (95% CI).
In the subgroup of patients on maintenance treatment,
annualised exacerbation rates were 0.66 and 0.68 with
indacaterol 150 mg and 300 mg, 0.80 with open-label tio-
tropium and 0.91 with placebo. Hazard ratios demonstrated
a statistically significant reduction in risk with activeTable 2 Effect of treatments on dyspnoea, health status and u
Indacaterol 150 mg
TDI total score at Week 26
Total score, LS mean (SE) 2.79 (0.269)
Difference vs. placebo,
LS mean (95% CI)
1.27 (0.70, 1.84)c
Rescue use over 26 weeks, puffs/day
LS mean (SE) 2.0 (0.16)
Difference vs. placebo,
LS mean (95% CI)
0.48 (0.84, 0.11)b
Change from baseline,f mean (SD) 1.0 (2.22)
Days without rescue use, %
LS mean (SE) 56 (2.4)
Difference vs. placebo,
LS mean (95% CI)
7.2 (1.7, 12.6)b,d
SGRQ total score at Week 26
Total score, LS mean (SE) 32.6 (1.03)
Difference vs. placebo,
LS mean (95% CI)
6.1 (8.4, 3.7)c,e
Mean (SD) change vs. baselinef 10.8 (15.28)
CIZ confidence intervals; LSZ least squares; TDIZ transition dyspn
Questionnaire.
a p < 0.05.
b p  0.01.
c p < 0.001 vs. placebo.
d p < 0.05.
e p < 0.01 vs. tiotropium.
f Raw mean data not analysed statistically.treatments compared with placebo: indacaterol 150 mg,
0.69 (95% CI 0.55, 0.87; p Z 0.002); indacaterol 300 mg,
0.68 (95% CI 0.54, 0.84; p < 0.001); open-label tiotropium,
0.70 (95% CI 0.53, 0.94, p Z 0.018).
Safety
The overall incidence of adverse events was similar in
patients receiving indacaterol 150 mg, indacaterol 300 mg
and placebo (49.6%, 49.8% and 47.8%, respectively) and
numerically slightly higher in patients receiving open-label
tiotropium (57.1%) (Table 3).
The most frequent individual adverse events were cough,
nasopharyngitis, COPD worsening, upper respiratory tract
infection and headache. Nasopharyngitis, influenza and
muscle spasms were numerically more frequent in the inda-
caterol 300 mg group than in the other groups, although none
was serious and in the opinion of the investigators few of the
cases were suspected to be related to treatment (nasophar-
yngitis and influenza, none; muscle spasms 3/12 patients).
With open-label tiotropium, hypertension (2/6 suspected
related), dry mouth (7/8 suspected related) and sinusitis
(none suspected related) were numerically more common
than in the other groups; none of the cases was serious.
Serious adverse events were uncommon, and occurred in
similar percentages of patients across all treatment groups
(indacaterol 150 mg, 6.0%; indacaterol 300 mg, 4.1%; open-
label tiotropium 6.4%; placebo, 5.6%). With the exception
of road traffic accidents (two patients), no individual
serious adverse event occurred in more than one patient.se of rescue medication.
Indacaterol 300 mg Tiotropium 18 mg
(open label)
Placebo
2.56 (0.265) 2.21 (0.322) 1.51 (0.239)
1.04 (0.47, 1.62)c 0.69 (0.02, 1.37)a e
1.9 (0.16) 2.2 (0.19) 2.4 (0.14)
0.59 (0.96, 0.22)b 0.19 (0.61, 0.22) e
1.2 (2.18) 0.8 (1.70) 0.5 (1.53)
59 (2.4) 50 (2.9) 49 (2.1)
9.8 (4.3, 15.3)c,e 0.5 (5.8, 6.8) e
36.2 (1.03) 37.1 (1.22) 38.7 (0.89)
2.5 (4.9, 0.2)a 1.6 (4.3, 1.1) e
8.0 (14.05) 6.8 (14.06) 5.2 (13.28)
oea index; SEZ standard error; SGRQZ St George’s Respiratory
0 1 2 3 4 5
2.47 (1.57, 3.89)
p < 0.001
2.50 (1.59, 3.94)
p < 0.001
1.82 (1.09, 3.04)
p = 0.023
Indacaterol 150 µg 
122/180 (67.8)
Indacaterol 300 µg 
122/177 (68.9)
Tiotropium 18 µg
(open label) 
73/115 (63.5) 
Odds ratio (95% CI)
Odds ratio versus placebo
Active, n/N (%) Placebo, n/N (%)
118/231 (51.1)
Figure 3 Odds ratios versus placebo for achieving the minimum clinically important difference (1 points) in TDI total score. A
rightward shift from the broken line (odds ratio Z 1, i.e. no difference from placebo) indicates improvement versus placebo.
Indacaterol and tiotropium as single maintenance in COPD 1711Compared with the maintenance-naı¨ve subgroup, the
overall burden of adverse events tended to be higher in
patients on maintenance treatment at baseline (online
Table S4), particularly those events reflecting manifes-
tations of COPD. Muscle spasms were more common with
indacaterol treatment but none of the events was
serious.
Discussion
Previous placebo-controlled studies showed that indaca-
terol 150 and 300 mg resulted in clinically meaningful
improvements in lung function, dyspnoea and health status
in patients with moderate-to-severe COPD (spirometric
classification GOLD II and III).11e13 The populations of
patients in those studies included those who had been
receiving maintenance treatment with ICS and bronchodi-
lators, with ICS treatment being continued during the
studies in patients taking this therapy at baseline. The
efficacy and safety of indacaterol treatment have also
previously been investigated in patient subgroups defined
by COPD severity, i.e. spirometric classifications GOLD II or
less and GOLD III or more.21 However, both of those severity
subgroups included a substantial proportion of patients
receiving maintenance ICS. This is the first time that the0 1
Odds rati
Indacaterol 150 µg 
127/184 (69.0)
Indacaterol 300 µg 
108/179 (60.3)
Tiotropium 18 µg
(open label) 
69/124 (55.6)
Active, n/N (%) Placebo, n/N (%)
121/247 (49.0))
Figure 4 Odds ratios versus placebo for achieving the minimum c
rightward shift from the broken line (odds ratio Z 1, i.e. no differefficacy and safety of indacaterol have been investigated in
patients who were previously receiving only a short-acting
bronchodilator as needed.
Our results demonstrate that patients not receiving
other maintenance therapy experienced significant
improvements with indacaterol, relative to placebo, in
trough FEV1, rescue medication use, dyspnoea and health
status after 6 months of treatment. Reduced use of rescue
medication has been postulated as an indirect measure of
symptom control.16
Both indacaterol doses provided important benefits for
these maintenance-naı¨ve patients, although the 150 mg
dose was significantly more effective than the 300 mg dose
for improving health status (SGRQ score). Reasons for this
apparent inverse doseeresponse are unclear; in the overall
pooled population from which this maintenance-naı¨ve
subgroup was drawn there was little difference in effect of
the two indacaterol doses on SGRQ scores.22 Looking at the
individual studies from which data were pooled, it can be
seen that one study, in which patients receiving indacaterol
did particularly well, contributed data for the 150 mg dose
but not for the 300 mg dose.11,23 The other two studies, both
of which included a 300 mg treatment arm, had numerically
lower results in all treatment arms (including placebo),
thus reducing the relative effect of the higher dose in the2 3 4 5
Odds ratio (95% CI)
2.77 (1.80, 4.26)
p < 0.001
1.61 (1.06, 2.46)
p = 0.026
1.33 (0.83, 2.14)
p = 0.231
o versus placebo
linically important difference (4 units) in SGRQ total score. A
ence from placebo) indicates improvement versus placebo.
Table 3 Incidence of adverse events overall and most commonly occurring (in 3% of patients in any treatment group).
Indacaterol 150 mg
(n Z 232)
Indacaterol 300 mg
(n Z 220)
Tiotropium 18 mg
(open label) (n Z 156)
Placebo
(n Z 325)
Adverse events, n (%) 115 (49.6) 119 (49.4) 89 (57.1) 161 (47.5)
Cough 13 (5.6) 12 (5.0) 6 (3.9) 14 (4.1)
Nasopharyngitis 11 (4.7) 20 (8.3) 9 (5.8) 22 (6.5)
Upper respiratory tract infection 10 (4.3) 10 (4.2) 9 (5.8) 13 (3.8)
COPD worsening 8 (3.4) 10 (4.2) 4 (2.6) 20 (5.9)
Headache 7 (3.0) 9 (3.7) 7 (4.5) 6 (1.8)
Nausea 7 (3.0) 0 1 (0.6) 6 (1.8)
Back pain 6 (2.6) 3 (1.2) 3 (1.9) 12 (3.5)
Influenza 4 (1.7) 10 (4.2) 2 (1.3) 5 (1.5)
Hypertension 4 (1.7) 2 (0.8) 6 (3.9) 8 (2.4)
Muscle spasms 3 (1.3) 12 (5.0) 5 (3.2) 3 (0.9)
Dry mouth 2 (0.9) 1 (0.4) 8 (5.1) 0
Sinusitis 1 (0.4) 5 (2.1) 7 (4.5) 5 (1.5)
1712 M. Decramer et al.pooled analysis.12,13 An inverse doseeresponse in the effect
of the LABA salmeterol on health status was attributed to
an increased frequency of tremor with the higher dose24,25;
in the present analysis, however, the safety profiles of the
two indacaterol doses were similar, including the incidence
of tremor (no cases in patients not on other maintenance
treatment).
Troosters and colleagues evaluated the efficacy of
double-blind tiotropium relative to placebo in a subgroup of
810 patients (403 on tiotropium, 407 on placebo) not
receiving maintenance treatment who were drawn from the
4-year UPLIFT study.6 Approximately 60% had COPD severity
of GOLD II and 35% GOLD III, a similar split to that in the
population in the present analysis. In that study, the effect
of blinded tiotropium on trough FEV1 at 6 months was
similar to that seen with open-label tiotropium in the
present study. The improvement in SGRQ total score
(by 2.3 relative to placebo over the first 6 months) with
tiotropium was not widely dissimilar from the difference of
1.6 seen in our study. In the UPLIFT subgroup, SGRQ was
subject to a substantial placebo effect close to the MCID,6
an effect that was also observed in the present study where
the SGRQ total score improved from baseline by 5 units with
placebo. Notwithstanding the large placebo effect, inda-
caterol provided a useful and clinically relevant additional
improvement in health status over placebo in these
patients. Their baseline SGRQ scores indicate a substantial
impairment in health status, which is consistently lower in
all stages of COPD compared with scores of approximately
10 (on the 0e100 scale) that have been measured for age-
matched healthy subjects and the general population.19,20
The large changes from baseline in all treatment groups,
including placebo, may reflect the improved care resulting
from involvement in a clinical trial, supporting the case for
early treatment of COPD.
Troosters and colleagues were also able to demonstrate
longer-term benefits of long-acting bronchodilator therapy
in the UPLIFT subgroup of maintenance-naı¨ve patients, with
a significantly slower decline in post-bronchodilator FEV1 in
patients receiving tiotropium (42 mL/year) than in those
receiving placebo (53 mL/year).6 The decline in SGRQ score
over 4 years was also significantly slower with tiotropiumthan with placebo in this subgroup. The evidence of
beneficial effects of long-acting bronchodilators as the first
maintenance therapy, both in this analysis and in that by
Troosters and colleagues,6 is important in light of the
recent reports of a more rapid deterioration of lung func-
tion in younger patients with early-stage COPD compared
with the more severe end of the disease spectrum,9,10
somewhat contrary to the classic Fletcher & Peto hypoth-
esis of the natural history of COPD progression observed
some 40 years ago.26 These findings were supported by
trends in data from the pharmacological intervention
studies UPLIFT and TORCH, in which the rate of FEV1
decline tended to be faster in patients with stage II COPD
than in those with more severe disease.7
The findings of faster decline of FEV1 in the early stages
of the disease provide a persuasive argument for increased
attention to early intervention with maintenance treat-
ment in COPD, where a long-acting bronchodilator such as
indacaterol or tiotropium has been shown to provide
important benefits. While the maintenance-naı¨ve patients
in the present analysis and that by Troosters and
colleagues6 most closely resemble the GOLD strategy
recommendations for use of long-acting bronchodilators in
COPD, other studies have shown beneficial treatment
effects in populations selected on the basis of younger age
and less severe (GOLD stage II) COPD.5,21,27,28
Indacaterol was generally well tolerated. The 150 mg
dose had a tolerability profile similar to that of placebo, in
terms of both overall incidence and the incidence of the
most common adverse events. Some of the most common
adverse events were more frequent with indacaterol 300 mg
and with open-label tiotropium than with placebo, but no
clinical significance was attached to the findings.
Potential limitations of our analyses should be noted.
The subgroup analyses were not pre-planned and no
statistical power calculations were conducted. As with all
post-hoc analyses, the findings should be considered
exploratory until confirmed under prospective conditions.
The use of open-label tiotropium may have introduced the
possibility of bias, particularly for subjective measures such
as health status, and this may have partly contributed to
the very small incremental effect of tiotropium over the
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study. The difference in SGRQ total score in the present
study between indacaterol and tiotropium of more than 4
units is indeed larger than the statistically significant 2-unit
difference demonstrated in a recent direct comparison of
indacaterol and tiotropium under robustly blinded condi-
tions.29 However, none of the patients in the present
analysis were taking tiotropium at entry to the studies, and
this may have reduced any bias to tiotropium as a study
treatment. Relatively small numbers of patients in the
present analysis received tiotropium compared with other
treatment groups. The subgroup from the UPLIFT data set
contained larger numbers of patients followed for a longer
period under double-blinded conditions, and any conclu-
sions regarding tiotropium that can be drawn from this
study must necessarily be more limited than those from the
UPLIFT subgroup analysis.6 Despite these limitations, the
data are included as being of potential interest, as they
enable a comparison in closely matched patient groups
between the two examples of once-daily maintenance
bronchodilator treatment for COPD currently available.
The use of last observation carried forward (LOCF) in the
analysis of outcomes is considered a more conservative
approach than an analysis of completing patients, since
over time placebo-treated patients are likely to deteriorate
(carrying forward a ‘better’ value) while actively treated
patients may improve (and would hence carry forward
a ‘worse’ value). However, both approaches have their
proponents. Analyses undertaken for the studies from
which these subgroups were drawn demonstrated that the
results were essentially unchanged for either LOCF or non-
LOCF approaches (unpublished data). Furthermore, results
for trough FEV1, TDI and SGRQ in the individual studies were
subjected to sensitivity analyses using repeated-measures
mixed models that used all available data and made prob-
ability estimates of the missing values and these again
generated the same conclusions (as the mixed-effect
treatment model used in the main analysis).
In conclusion, indacaterol provided clinically meaningful
improvements compared with placebo in lung function,
dyspnoea and health status, and was well tolerated, when
given to patients with COPD who were not receiving other
maintenance treatments. Indacaterol 150 mg appeared to
have some incremental margin of efficacy over the 300 mg
dose of indacaterol, and would be an appropriate choice for
initial maintenance therapy in patients with COPD. These
results should be confirmed in a prospective investigation.
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